Mary Jo Pilat

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

David S. Hong, Razelle Kurzrock, Aung Naing et al. · Investigational New Drugs · 2013 · 211 citations

Medicine, Oncology, Pharmacology +15

The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth.

Prakash K. Pandalai, Mary Jo Pilat, K. Yamazaki et al. · PubMed · 1996 · 143 citations

Life Sciences, Nutritional Sciences, Oncology +17

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Patricia LoRusso, Jing Li, Angelika M. Burger et al. · Clinical Cancer Research · 2016 · 109 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Geoffrey I. Shapiro, Patricia LoRusso, Eunice L. Kwak et al. · Investigational New Drugs · 2019 · 92 citations

Medicine, Oncology, Pharmacology +12

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

Priscila Gonçalves, Lance K. Heilbrun, Michael T. Barrett et al. · Oncotarget · 2017 · 69 citations · Full text

Medicine, Oncology, Pharmacology +6